ROCO
4171
Market cap35mUSD
Oct 08, Last price
19.85TWD
1D
7.88%
1Q
16.08%
Jan 2017
40.48%
IPO
-31.46%
Name
GeneReach Biotechnology Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes in the development, production, and commercialization of advanced nucleic acid detection technologies. The company's extensive product line features essential laboratory instrumentation, including automated nucleic acid extraction systems, prep homogenization systems, and mini centrifuges. GeneReach also provides a wide range of reagents and consumables, such as human In Vitro Diagnostic (IVD) assays, specific iiPCR reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and various research-grade reagents and supplies. Beyond its product offerings, GeneReach delivers comprehensive services. These encompass polymerase chain reaction (PCR) training programs, expert molecular diagnostic technical solutions, laboratory installation assistance, OEM/ODM contract manufacturing capabilities, and collaborative research services. Its innovative solutions cater to a diverse clientele, with applications spanning aquaculture, agriculture, food safety, human health, and the welfare of companion animals and livestock. GeneReach Biotechnology Corp. was established in 2004.
Key people
Baihua Chen
Deputy General Manager - Research and Development Group · since 2025
Pinxing Chou
Senior Deputy General Manager of Operations · since 2025
Shuyu Cao
Head of Accounting · since 2015
Yuyan Fu
Special Assistant to Chairman of the Board · since 2019
Xiuying Zhang
Head of Finance, Corporate Governance Officer · since 2023
Simon Chung
Chief Executive Officer, Director · since 2022
Conghan Liu
Director · since 2019
Leo Liu
Chairman of the Board · since 2013
Jiajun Cai
Independent Director · since 2013
Huiyu Huang
Independent Director · since 2025
Zhiyao Huang
Independent Director · since 2025
Zhufang Luo
Independent Director · since 2022
Yaosheng Ye
Independent Director · since 2019
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||